

Reviewer 2 v.1

Comments to the Author

This review mainly outlines cardiovascular morbidities of OSA as well as the potential role of EVs served as clinically and mechanistically relevant biomarkers in OSA-associated CVD, along with the emerging diagnostic and therapeutic opportunities. This is a very interesting topic and of great clinical significance. However, the manuscript would be better organized and polished in order to qualify the quality of the TAR journal. Besides, this review also used a large space to introduce the impact of OSA and its associated fundamental research model (such as IH profiles et al.) on the end-organ function and other comorbidities (such as tumor growth et al.), which seems not to be closely associated with the main topic and might be better to be shortened. Thirdly, this review mentioned several times that the therapeutic effect of CPAP treatment on the outcome of CVD in OSA patients was a controversial issue. In this regard, are there any fundamental research results that could provide evidence or hypothesis to illustrate the role EVs plays in this issue? If the associated interpretable theory or hypothesis could be added into this review, the review could be more conclusive and meaningful.